Latest Candel Therapeutics News & Updates

See the latest news and media coverage for Candel. We track all announcements, press releases, and industry mentions in real time, all in one place.

Candel Therapeutics (Candel)

Clinical-stage biotech developing viral immunotherapy platforms for solid tumors

candeltx.com

Headquarters: Needham, United States
Founded year: 1999
Company type: Public company
Number of employees: 100–200
Industry: Biotechnology & Medical Research

Last updated October 21

Latest news about Candel Therapeutics (Candel)

In short: Candel reported prostate-cancer Phase 3 data and initiated a pivotal lung-cancer trial.

Company announcements

October 6 Candel

Candel appoints Martine Zimmermann to its board of directors

Zimmermann joins with over three decades of global regulatory affairs and quality experience spanning various drug development stages.

October 1 Candel

Candel reports Phase 2a survival data for NSCLC immunotherapy

Median overall survival reached 24.5 months in advanced non-small cell lung cancer patients failing immune checkpoint inhibitors, supporting the pivotal phase 3 AURORA trial.

September 30 Candel

Candel announces positive phase 3 data for prostate cancer drug

Aglatimagene reduces recurrence risk by 41% and induces systemic immune activation, supporting a Q4 2026 FDA application.

August 20 Candel

Candel advances its prostate cancer immunotherapy development pipeline

The company reports that phase 3 trials demonstrated meaningful improvements in disease-free survival for patients receiving the viral therapy alongside radiotherapy.

Media coverage

October 21 StreetInsider

Candel upgraded at BofA on prostate cancer gene therapy (CADL:NASDAQ)

BofA upgrades Candel Therapeutics to Buy, citing CAN-2409 prostate cancer gene therapy and 2027...

Never miss news about Candel

Track Candel and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Candel competitors & trending companies

Browse news for competitors to Candel and other trending companies.